Efficacy of thymosin α1 in patients with chronic hepatitis B: A randomized, controlled trial

随机对照试验 医学 慢性肝炎 胸腺肽 内科学 胃肠病学 病毒学 病毒
作者
Rong‐Nan Chien,Yun‐Fan Liaw,Tse‐Ching Chen,Chau‐Ting Yeh,I.-Shyan Sheen
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
卷期号:27 (5): 1383-1387 被引量:132
标识
DOI:10.1002/hep.510270527
摘要

Thymosin alpha1 (Talpha) is an immune modifier that has been shown in a pilot study to be effective for chronic hepatitis B; this requires confirmation. Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups: 1) group A received a 26-week course of Talpha with a 1.6-mg subcutaneous injection two times a week (T6 group); 2) group B received the same regimen as group A, but Talpha therapy extended for 52 weeks (T12 group); and 3) group C served as a control group and was followed up for 18 months without specific treatment (T0 group). The three groups were comparable in clinicohistological features at entry. The complete virological response rate (clearance of serum hepatitis B virus [HBV] DNA and hepatitis B e antigen [HBeAg]) was higher in group A (40.6%) and group B (26.5%) than in group C (9.4%) (group A vs. group C: P=.004; group B vs. group C: P=.068) when assessed 18 months after entry, although complete response rates among these three groups were similar when first assessed at the end of therapy. There was a trend for complete virological response to increase or accumulate gradually after the end of Talpha therapy. None of the responders lost hepatitis B surface antigen. Blinded histological assessment showed a significant improvement in treated patients, particularly in lobular necroinflammation and scores excluding fibrosis. No significant side effects were observed. These results suggest that a 26-week course of Talpha therapy is effective and safe in patients with chronic hepatitis B.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
上岸完成签到,获得积分10
1秒前
张会发布了新的文献求助10
1秒前
包容珩完成签到,获得积分10
1秒前
牧百川发布了新的文献求助10
1秒前
00发布了新的文献求助10
2秒前
2秒前
3秒前
万能图书馆的应助被xx采纳,获得10
3秒前
QQ发布了新的文献求助10
4秒前
星空发布了新的文献求助10
5秒前
5秒前
5秒前
wywyww发布了新的文献求助10
5秒前
4yjmngbfd发布了新的文献求助10
6秒前
啵啵完成签到,获得积分10
6秒前
6秒前
饲料批发发布了新的文献求助10
6秒前
6秒前
苗条梨愁发布了新的文献求助10
7秒前
7秒前
机智铃铛发布了新的文献求助10
7秒前
Felix0917发布了新的文献求助10
8秒前
yjz发布了新的文献求助10
10秒前
烟花的应助被Hana采纳,获得10
11秒前
生生不息发布了新的文献求助10
11秒前
12秒前
13秒前
牧百川发布了新的文献求助10
13秒前
13秒前
13秒前
choumaoo完成签到,获得积分10
14秒前
Akim的应助被fionawu采纳,获得30
14秒前
甘露寺检票员完成签到,获得积分10
14秒前
15秒前
文轩完成签到,获得积分10
15秒前
榴榴完成签到 ,获得积分10
15秒前
16秒前
ping完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183621
求助须知:如何正确求助?哪些是违规求助? 9572918
关于积分的说明 21828010
捐赠科研通 7780809
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558243
邀请新用户注册赠送积分活动 2480496